Erasmus GBS Outcome Score (EGOS)
Predicts probability of independent ambulation at 6 months in Guillain-Barre syndrome. Guides ICU admission and rehabilitation planning.
Score interpretation
→ IVIG 0.4g/kg x 5 days or plasmapheresis; physiotherapy; pain management; DVT prophylaxis; most patients walk at 6 months
→ IVIG or plasma exchange; ICU monitoring; respiratory function monitoring (FVC, NIF); may need ventilation; rehab planning; bladder care; nutritional support
→ ICU admission; ventilatory support if FVC <20ml/kg or NIF <30cmH2O; autonomic monitoring (arrhythmia, BP swings); prolonged rehab; second IVIG if plateaued; tracheostomy if prolonged ventilation
Interpretation bands for the GBS EGOS Score. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Gelatin (succinylated) · Colloid plasma volume expander
- Lanadelumab · Anti-plasma kallikrein monoclonal antibody
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
- C1-esterase inhibitor · Plasma-derived complement inhibitor
- Berotralstat · Oral plasma kallikrein inhibitor
- Albumin solution · Plasma derivative / colloid
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.